<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The efficacy and toxicity of <z:chebi fb="0" ids="2636">amifostine</z:chebi> (300 mg/m(2) three times a week for three consecutive weeks for a maximum of six courses) was evaluated in 12 patients with primary <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Dose escalation up to 400 mg/m(2) was allowed to patients who failed to respond </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="35143">Hemoglobin</z:chebi> concentration was increased &gt; or = 1.5 g/dl in two (18%) of the 11 anemic patients </plain></SENT>
<SENT sid="3" pm="."><plain>These two patients obtained transfusion independence for 20 weeks </plain></SENT>
<SENT sid="4" pm="."><plain>Reticulocyte counts and ANC increased &gt; or = 50% of baseline in four (44%) of the nine patients with <z:hpo ids='HP_0001896'>reticulocytopenia</z:hpo> and in three (25%) of the 12 neutropenic patients </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0836924" disease_type="Disease or Syndrome" abbrv="">Platelet count increased</z:e> in three (50%) of the six patients with <z:hpo ids='HP_0001873'>thrombocytopenia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Progenitor growth of CFU-GMs and BFU-Es improved in 8/12 patients </plain></SENT>
<SENT sid="7" pm="."><plain>No major side effects were observed </plain></SENT>
<SENT sid="8" pm="."><plain>In conclusion <z:chebi fb="0" ids="2636">amifostine</z:chebi> is well tolerated and can promote the growth of primitive hematopoietic progenitors and ameliorate the cytopenias in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
</text></document>